Summary:A total of 75 patients underwent sibling allogeneic stem cell transplantation (SCT) for chronic myeloid leukaemia in first chronic phase from 1984 to 2000. Of these patients, 51 (68%) were alive at a median follow-up of 98 months (range 34-217 months). Nine (18%) patients relapsed and seven (14%) received donor lymphocyte transfusions. Quality of life (QoL) was assessed crosssectionally using the EORTC QLQ-C30, a Leukaemia-BMT-specific module and questionnaires on sexual functioning, fertility and late effects. A total of 46 (90%) replied. Scores for Role (P ¼ 0.018) and Cognitive (Po0.001) function were significantly lower when compared to an age-adjusted general population. Dyspnoea (P ¼ 0.022) and Financial Difficulties (Po0.001) were significantly more common in the SCT group. No difference was found for scores in the Physical, Emotional and Social domains or the overall Global Health Status/ QoL. Decreased sexual functioning was found in one-third of respondents. Although most BMT recipients reported a good QoL, a minority have difficulty with reintegration into professional roles and consequent monetary problems. Identified cognitive and sexual impairments highlight the need for long-term access to psychosocial support. Bone Marrow Transplantation (2004) 34, 545-556. doi:10.1038/sj.bmt.1704638 Published online 9 August 2004 Keywords: chronic myeloid leukaemia; quality-of-life; allogeneic SCT Recent years have seen an increase in the therapeutic options available for the treatment of patients with chronic myeloid leukaemia (CML). 1 Allogeneic stem cell transplantation (SCT), however, remains the standard of care for younger patients with an HLA-compatible donor. The most recent EBMT registry survey reported that the median survival of patients who underwent non-T-celldepleted transplantation for CML in first chronic phase (CP) from an HLA-matched sibling donor had not been reached at 10 years. 2 Health-related quality of life (QoL) has been defined as referring 'to the extent to which one's usual or expected physical, emotional and social well-being are affected by a medical condition or its treatment'. 3 Most of the previous studies are cross-sectional in design, apply one of several available instruments and pool all patients transplanted for different diagnoses at a single centre. [4][5][6][7][8][9][10][11][12] Although marked morbidity in the first few years is evident, there is a clear trend to improved QoL in long-term survivors of transplantation. 6,8 Nonetheless, aggregated studies confirm that a minority of individuals continue to suffer from the effects of chronic graft-versus-host disease (GvHD) and sexual dysfunction. Our observations confirm and extend those of Kiss et al 12 in a group of 24 patients receiving SCT for CML in first CP.The European Organisation for Research and Treatment of Cancer (EORTC) QoL questionnaire -QLQ-C30 13 -was used in this study. Both EORTC population reference data and CML-specific data have been generated using this instrument. [14][15][16] In addition to t...
Reduced intensity conditioning allogeneic stem cell transplantations (allo-SCT) have been developed to exploit graft-versus-malignancy effect while reducing the toxicity of allo-SCT. We report the outcome of 21 patients with low-grade B cell lymphoproliferative disorders transplanted in a single center. The mean age of the patients was 54 years (range 32–66) with 11 males, 10 females. Follicular lymphoma was the diagnosis in 10 patients, CLL in 5, mantle cell lymphoma in 4, MALT lymphoma in 1 and lymphoplasmocytoid lymphoma in 1 patient. The median number of prior treatment lines was 2. All patients received peripheral blood stem cell transplants from sibling donors and no patients had undergone a prior autologous SCT. 12/21 patients (57%) received a ATG based conditioning regimen while the remainder, 9/21 (42%) received a Campath containing conditioning regimen. Full donor chimerism was confirmed in 17/19 (89%) patients. Acute graft versus host disease (GVHD) developed in 5/21 (23%) of the patients. Chronic GVHD occurred in 7/21 (33%) with 5/21 occuring post donor lymphocyte infusion (DLI). DLI has been administered in 11/21 patients (52%), 2 for progressive disease and 9 for re-emerging mixed chimerism. Non-relapse mortality (NRM) at 100 days and 1 year were 5% and 12.5% respectively. With a median follow up of 21 months (range 3–54) the overall survival rates (OS) at 1 year and 2 years were 72% and 58% respectively. Progression free survival (PFS) at 1 year and 2 years were 66% and 50%. We have shown that reduced intensity conditioning allogeneic stem cell transplantation is associated with a low TRM comparible to that of autologous transplantation and allows long term control of low grade B-cell lymphoproliferative disorders.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.